Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity.

L Greenfield1, V G Johnson, R J Youle

  • 1Department of Microbial Genetics, Cetus Corporation, Emeryville, CA 94608.

Science (New York, N.Y.)
|October 23, 1987
PubMed
Summary

Engineered immunotoxins combine potent cancer cell killing with high specificity. Modified diphtheria toxin B chains enable targeted delivery and toxicity without harming non-target cells, improving cancer therapy potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anhedonia and anergia predict mortality in older Australians living in residential aged care.

Aging & mental health·2021
Same author

Use of the web in the self-management of bipolar disorder.

Acta neuropsychiatrica·2016
Same author

Farmer and Public Attitudes Toward Lamb Finishing Systems.

Journal of applied animal welfare science : JAAWS·2016
Same author

The C-terminal helix of Bcl-x(L) mediates Bax retrotranslocation from the mitochondria.

Cell death and differentiation·2012
Same author

The 'real world' utility of a web-based bipolar disorder screening measure.

Acta psychiatrica Scandinavica·2012
Same author

Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak.

Oncogene·2011

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Immunology

Background:

  • Immunotoxins, combining monoclonal antibodies with toxic proteins, aim to selectively eliminate tumor cells.
  • Previous attempts to create potent and specific immunotoxins were hindered by inseparable toxin functions.
  • Diphtheria toxin's B chain facilitates cell entry and binds to non-target cell receptors, causing toxicity.

Purpose of the Study:

  • To design novel immunotoxins with enhanced cell-type specificity and retained potency.
  • To separate the cell entry function from the receptor binding function of diphtheria toxin.

Main Methods:

  • Point mutations were introduced into the B polypeptide chain of diphtheria toxin.
  • Mutant diphtheria toxins were assessed for toxicity and binding activity.

Related Experiment Videos

  • Mutant toxins were linked to a monoclonal antibody targeting human T cells.

    • Main Results:

    • Mutant diphtheria toxins showed significantly reduced toxicity and binding affinity.
    • Immunotoxins created with inactivated mutants retained full target-cell toxicity.
    • Non-target cell toxicity was substantially reduced in the engineered immunotoxins.

    Conclusions:

    • Separating diphtheria toxin's entry and binding functions yields potent, cell-specific immunotoxins.
    • This approach significantly reduces toxicity to non-target cells while maintaining efficacy.
    • These findings offer a promising strategy for developing safer and more effective immunotoxin therapies.